http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0066101-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f47c750954e13a1ed0be96c1bf1c51c7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
| filingDate | 2000-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e9f0c36bf4e6cef39ae76758a9d379d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_043fd3aa82504cb35e5665f05392947d |
| publicationDate | 2002-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0066101-A3 |
| titleOfInvention | Method of inhibiting glycation product formation |
| abstract | This invention provides a method of preventing the formation of advanced glycation products through administering a xanthine-based compound, for example, lisofylline. The method is useful in treatments for diseases associated with advanced glycation end-products, such as diabetes, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Down's syndrome, osteoarthritis, cataracts, cardiac hypertrophy, arterial stiffening, atherosclerosis and kidney toxicity. |
| priorityDate | 1999-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.